Genetic tumor innovation creating infrastructure — neurofibromatosis type II therapeutics providing targeted therapy managing bilateral vestibular schwannomas and tumor growth, establishing NF2 therapy as essential rare genetic disease infrastructure, with the Neurofibromatoses Type II Therapeutics Market experiencing expansion driven by NF2 prevalence, tumor management emphasis, and...